Q1 2025 Management View CEO Chris Viehbacher highlighted Biogen's evolving portfolio, with newer products such as LEQEMBI, SKYCLARYS, and ZURZUVAE now comprising 45% of product revenue. He emphasized ...

Biogen stock could pop Thursday after the biotech company beat first-quarter expectations, including strong sales for two newcomer drugs.

Medications like donanemab (Kisunla) and lecanemab (Leqembi) target amyloid plaques that build up in the brain due to ...

A report from the Alzheimer’s Association says new treatments and blood tests could change how doctors detect and treat the ...

Burdened by competitive pressures for its stalwart multiple sclerosis franchise, Biogen has weathered years of sales declines ...

Announcing first-quarter results, Biogen CEO Chris Viehbacher admitted that tariffs are “a new topic for us,” but said he ...

In addition, Eisai must conduct a post-authorization safety study, including setting up a patient registry for the European Union. Now each European country must set its own rules for access and ...

Lecanemab, currently licensed as a biweekly 10 mg/kg IV infusion, is developed by Eisai and Biogen to address the unmet needs of AD patients. AD, a chronic, progressive disease and the UK’s leading ...

A new Alzheimer’s Association report shows the number of people living with Alzheimer’s disease has reached 7.2 million ...

UK regulators are set to review a proposed label update for Eisai (TYO: 4523) and Biogen’s (Nasdaq: BIIB) Alzheimer’s drug ...

We recognize and have recognized for some time that Alzheimer’s disease is a public health crisis,” said Meggie Gaskins.

Biogen Inc (BIIB) reports a 6% revenue increase driven by new product launches, despite facing competitive pressures in its MS franchise.